Major population health real-world studies such as SCoMIS, which examines the use of Wegovy in the Scottish population will read-out by 2029, and SURMOUNT-REAL will provide definitive insights into whether use of Obesity Medicines brings healthcare system benefits in the form of, for example, reduced cardiovascular events, diabetes or disability, and may also provide data on wider socio-economic benefits, such as reduced unemployment
Vitamin B12 Deficiency and Mood Disorders: A deficiency in vitamin B12 can contribute to a variety of neurological and psychiatric symptoms, such as mood changes, irritability, and even depression
While generally well-tolerated in research settings, comprehensive human safety data is lacking
With the right treatment plan, many patients see steady, noticeable progress that supports real health changes over time
Selected Data 1) Previous research has determined the ability of AngIV analogs such as Dihexa, to increase cerebral blood flow, elicit neuroprotective effects, and promote long term potentiation, learning, and memory consolidation
Obesity drugs that have recently attracted attention, such as Novo Nordisk's "Wigobi," are drugs that mimic this GLP-1